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■ INTRODUCTION
The combination of ampicillin with sulbactam
(prodrug sultamicillin) expands the spectrum
of the former to include beta-lactamase produc-
ing microorganisms, such as Haemophilus in-
fluenzae and Moraxella catarrhalis [1, 2]. The
plasma levels of ampicillin and sulbactam,
when given as sultamicillin, are two to three
times higher than with an equivalent dose of ei-
ther drug alone [3]. 
The clinical efficacy and safety of the generally
recommended daily dose of sultamicillin, 50
mg/kg administered in the treatment of chil-
dren, and 1500 mg in the treatment of adults,
have been established by numerous studies [4,
5, 6, 7, 8]. In Turkey, the recommended daily
dose of sultamicillin is 25 mg/kg in the treat-
ment of children, and 750 mg in the treatment
of adults. We have found some studies, report-
ing the efficacy of low dose administration [4, 9,
10, 11], but none of them were comparative.
The aim of this clinical study was to evaluate
the efficacy and safety of orally administered
sultamicillin (Pfizer), marketed in low doses in
Turkey, and compare it with orally adminis-
tered amoxicillin (ABFAR, a Turkish company)
in the treatment of acute sinusitis
■ METHODS
Patients: One hundred and twenty-five patients
(58 male and 67 female), between the ages of 16-
63 (mean 36.2), suffering from acute sinusitis,
took part in the trial. All patients were outpa-
tients and self-referrals. The diagnosis of infec-
tion was based on medical history, physical ex-
amination, conventional radiographic evalua-
tion and leukocyte count. Most of the patients
complained of prolonged common cold, de-
spite having symptomatic therapy. At the be-
ginning, they had watery discharge, changing
to purulent in the following week. 
Signs and symptoms of the infection (purulent
postnasal or nasal discharge; nasal inflamma-
tion; frontal/maxillary tenderness or pain;
headache) were assessed and graded (0: ab-
sent, 1: mild, 2: moderate, 3: severe) before,
during (five days after the first dose of study
drugs), and at the end of therapy (10 days after
the first dose of study drugs), and 20 days after
the last dose (follow-up). A physician indicated
chemotherapy, and another physician who
was blind randomly prescribed study drugs.
The first physician carried out control evalua-
tions.
Exclusion criteria for the study were:
1) treatment with another antimicrobial agent
within one week prior to enrolment, or receiv-
ing prophylactic antimicrobial agent;
2) symptoms no longer than a week that may be
attributed to a common cold;
3) known hypersensitivity to any beta-lactam
antibiotic;
4) infections requiring treatment with another
antimicrobial agent;
5) terminal illness, immune deficiency or other
disease that precluding evaluation of the study
drug therapy;
6) pregnancy. 
Each patient or patient’s parent gave informed
consent. 
Treatment and evaluation: At the beginning,
the patients were randomized to receive daily,
oral dose of sultamicillin and amoxicillin,








the remaining 25 patients  received sultami-
cillin. Demographic data, severity grade of pa-
tients, by treatment, are shown in table 1.
In both treatment groups patients were treated
for ten days. The first control was made 5 days
after the first dose of study drugs. A patient
was considered clinically cured when all pre-
treatment signs and symptoms of infection
were eliminated. Clinical improvement was de-
fined as partial disappearance of pretreatment
signs and symptoms. In either result study
drugs were reconstituted for 5 additional days.
Failure was defined as no change or worsening
of signs and symptoms; and the study drug was
changed. Relapse was defined as improvement
or cure with subsequent reappearance of signs
and symptoms at the follow-up assessment. A
patient who was either cured or improved was
considered a clinical success. No other con-
comitant medications were allowed, except for
a few patients who received acetaminophen. 
Independent-Samples T test was used to com-
pare demographic information such as age. The
chi-square test was employed to compare the
sex distribution of patients and the rates of ad-
verse events according to treatment. The
Wilcoxon two-sample test was used to compare
the distribution of clinical efficacy and
signs/symptoms between two treatment
groups. The level of significance was set at 0.05.
■ RESULTS
One hundred and eight patients, 46 male and 62
female, between the ages of 16-56 (mean 32.8),
came to their control visits regularly. There
were 66 patients in the sultamicillin group, 42
in amoxicillin group. The age, weight and sex of
patients were comparable in treatment groups. 
The clinical success (improvement+cure) rate
was (17+11)/42 (66.6%) and (28+21)/66 (74.2%)
for amoxicillin and sultamicillin respectively, at
the first control, as shown in table 2. All im-
proved patients were cured at the second con-
trol. The side effects were seen in two patients
(3.0%) in the sultamicillin group and in five
(11.9%) in the amoxicillin group. All side effects
were in the gastrointestinal system. Treatment
was discontinued in no patient for adverse
drug reaction. Relapses were observed in four
patients (6.0%) in the sultamicillin group and
three (7.1%) in the amoxicillin group. 
Responses to both treatments were similar and
there were no significant differences between
the treatment groups with respect to resolution
of symptoms, side effects and relapse (p>0.05).
■ DISCUSSION
Pharmacokinetic studies have established that
ampicillin peak plasma concentrations
achieved after oral administration of sultami-
cillin are approximately three times those ob-
tained with equimolar dose of oral ampicillin
[3]. Although the elimination half-lives of
ampicillin and sulbactam are each approxi-
mately 1 hour, the high serum concentrations
achieved, coupled with their synergistic bacte-
ricidal activity, permit twice-daily dosing [3].
However, although the proposed daily dose of
sultamicillin is 50 mg/kg in the treatment of
children and 1500 mg in the treatment of adults
[4, 5, 6, 7], in Turkey it has been marketed in
low (25 mg/kg for children, 750 mg for adults)
and twice-daily dose form for more than 10
years.  
There are some studies reporting similar clini-
cal and bacteriological cure rates in the treat-
C
Table 1 - Demographic data by treatment (age, gender, severity grade of sinusitis).
Treatment Mean age Male/female Mild n (%) Moderate n (%) Severe n (%)
Sultamicillin 37.1 37/38 17 (22.6) 51 (68.0) 7 (9.3)
Amoxicillin 35.4 21/29 9 (18.0) 37 (74.0) 4 (8.0)
Table 2 - Numbers and percentages of cures, improvements and failures by treatment and disease severity 
(I: Improvement, C: Cure, F: Failure). The percentages show success rates.
Treatment Mild n (%) Moderate n (%) Severe n (%)
Sultamicillin I/C/F 5/9/3 (82.3) 13/24/14 (72.5) 3/1/3 (57.1)
Amoxicillin  I/C/F 2/5/2 (77.7) 7/21/9 (75.6) 2/0/2 (50.0)
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vent relapses. Though not significant, sultami-
cillin was found to be more effective than
amoxicillin. The beta lactamase-producing or-
ganisms may be an explanation of that result. It
is well known that there are some beta lacta-
mase-producing organisms in acute sinusitis
[12,15]. 
The side-effects of low-dose sultamicillin were
considerably lower than the generally accepted
dose, 4-8%  [9, 10, 13] and 7-65% [5, 7, 8] re-
spectively. The low incidence of side effects
with low dosage of sultamicillin is confirmed in
the present study. This finding requires further
investigation. The treatment cost of sultami-
cillin was higher than that of amoxicillin. 
Key words: amoxicillin, sultamicillin, acute sinu-
sitis.
ment of mild to moderate community-acquired,
acute ear-nose-throat infections, using a low
and twice-daily dosage of sultamicillin [4, 9, 10,
13]. In such studies, overall clinical and bacteri-
ological cure rates were high (94-99%). How-
ever, none of them was comparative. The only
comparative study that we found was held in
Turkey. In that study, only 24 acute maxillary
sinusitis patients were involved; and success
rate was 83.3% for sultamicillin and 66.6 % for
amoxicillin (P>0.05) [14]. Our cure rates were
not as high as in preceding studies. We con-
sider that comparative studies are more reli-
able. 
In this study, although some patients were
cured by five-day treatment, the duration of the
treatment should be at least ten days in order to
obtain a cure for improved patients and pre-
Objectives: to study the effectiveness of low dose
sultamicillin in the treatment of acute sinusitis.
Methods: a total of 108 patients, between 16-56
years of age (mean 32.8), suffering from acute si-
nusitis took part in the trial. Patients received
orally 2x375 mg sultamicillin, and compared with
patients receiving 3x500 mg amoxicillin. The first
control was made between the 5th and 7th days. A
patient was considered clinically cured when all
pretreatment signs and symptoms of infection
were eliminated. Clinical improvement was defi-
ned as the partial disappearance of pretreatment
signs and symptoms. In either result, study drugs
were reconstituted for additional 5 days. Failure
was defined as no change or worsening of signs
and symptoms; and study drug was changed. The
second control was made between 10-12th days,
and the third was four weeks later.
Results: The clinical success (improvement +
cure) rate was (17+11)/42 (66.6%) and
(28+21)/66 (74.2%) for amoxicillin and sultami-
cillin respectively, at first control. All improved
patients were cured at the second control. No si-
gnificant side-effects were noted in either amoxi-
cillin or sultamicillin treated patients. All side ef-
fects were gastrointestinal, 11.9% and 3.0% in
the same order.
Conclusions: Low dose sultamicillin was compa-
rable to amoxicillin; sultamicillin has fewer side
effects than amoxicillin (p>0.05).
SUMMARY
Obiettivi: studiare l’efficacia terapeutica della
sultamicillina a basso dosaggio nel tratta-
mento della sinusite acuta. 
Metodi: 108 pazienti di età compresa tra 16 e
56 anni (media 32.8) affetti da sinusite acuta
sono stati arruolati nel presente studio. I pa-
zienti suddivisi in due gruppi sono stati sot-
toposti a trattamento orale con sultamicillina
(2x375 mg) o con amoxicillina (3x500 mg). Il
primo controllo clinico è stato effettuato tra il
5° e il 7° giorno dall’inizio della terapia. La
guarigione clinica è stata definita sulla base
della scomparsa di tutti i segni e sintomi
dell’infezione precedenti l’inizio del tratta-
mento. Miglioramento clinico è stato definito
come parziale scomparsa dei segni clinici.
Nel caso di mancata guarigione o migliora-
mento il trattamento con i farmaci in studio è
stato proseguito per ulteriori 5 giorni. Il falli-
mento è stato definito come nessuna varia-
zione o peggioramento dei segni e sintomi. Il
secondo controllo clinico è stato effettuato tra
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Risultati: al primo controllo è stato osservato
successo clinico (miglioramento +guarigione)
in (17+11)/42 (66.6%) ed in (28 + 21)/66
(74.2%) pazienti rispettivamente trattati con
amoxicillina e sultamicillina; al secondo con-
trollo tutti i pazienti migliorati sono risultati
guariti. Si è osservata una differenza statisti-
camente significativa nell’incidenza di effetti
collaterali (prevalentemente gastrointesti-
nali) nei due gruppi di trattamento (11.9%
per amoxicillina, 3% per sultamicillina)
(P>0.05).
Conclusioni: i risultati terapeutici ottenuti con
sultamicillina a basse dosi sono stati parago-
nabili a quelli dell’amoxicillina. La sultami-
cillina ha mostrato minori effetti collaterali.
